// App-Quantinova.ai

Su1904 : APPROPRIATENESS OF CONCOMITANT IMMUNOMODULATOR AND BIOLOGIC THERAPY IN Crohn's DISEASE AND ULCERATIVE COLITIS

Researchers

Presenter

  • Gilaad Kaplan

Principal Investigators

  • Miles Sparrow

  • Laura H. Raffals

  • Corey A. Siegel

  • Fernando Velayos

  • Leonard Baidoo

  • Brian Bressler

  • Adam S. Cheifetz

  • Shane M. Devlin

  • Peter M. Irving

  • Jennifer L. Jones

  • Patricia Kozuch

Medical Centers

  • Alfred Hospital, Melbourne, New South Wales, Australia

  • Dartmouth Hitchcock Medical Center, Hanover, New Hampshire, United States

  • Thomas Jefferson University, Philadelphia, PA, United States

  • University of British Columbia, Vancouver, British Columbia, Canada.

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

  • University of Calgary, Calgary, AB, Canada

  • Guy's Hospital, London, United Kingdom

  • Beth Israel Deaconess, Boston, Massachusetts, United States

  • QE II Health Science Center, Nova Scotia, Nova Scotia, Canada

  • University of California, San Francisco, San Francisco, California, United States

  • Cedars Sinai Medical Center, Los Angeles, California, United States

  • Rush University Medical Center, Chicago, Illinois, United States

Locations

  • United States

  • Canada

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Oraprine

  • Certolizumab pegol

  • Methotrexate

  • Entyvio

  • Adalimumab

  • Infliximab

  • golimumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved